Entrepreneur UK's London 100: The London Interdisciplinary School
Industry: Education
The London Interdisciplinary School (LIS) offers an interdisciplinary undergraduate programme that integrates academic study with industry experience.
The LIS was founded to equip students with the skills needed to tackle complex societal issues, beyond traditional career paths. Using a problem-based learning model, the LIS enables students to tackle global challenges - such as climate change, inequality, and technological ethics - through multiple disciplines.
The curriculum blends problem-based learning with qualitative and quantitative methods, similar to the broader approach of Liberal Arts education in the US.
The LIS focuses on skills like teamwork, creativity, adaptability, and critical thinking, preparing students for a dynamic workforce instead of relying on specific A-levels.
The LIS was founded by Ed Fidoe, an education entrepreneur and former child actor, known for his role as Erik Banks in the 1980s/90s children's TV series Woof!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
If EPS Growth Is Important To You, Johnson Matthey (LON:JMAT) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Johnson Matthey (LON:JMAT). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Recognition must be given to the that Johnson Matthey has grown EPS by 54% per year, over the last three years. Growth that fast may well be fleeting, but it should be more than enough to pique the interest of the wary stock pickers. Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. Johnson Matthey's EBIT margins are flat but, worryingly, its revenue is actually down. Suffice it to say that is not a great sign of growth. The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers. View our latest analysis for Johnson Matthey Fortunately, we've got access to analyst forecasts of Johnson Matthey's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting. Investors are always searching for a vote of confidence in the companies they hold and insider buying is one of the key indicators for optimism on the market. This view is based on the possibility that stock purchases signal bullishness on behalf of the buyer. Of course, we can never be sure what insiders are thinking, we can only judge their actions. Shareholders in Johnson Matthey will be more than happy to see insiders committing themselves to the company, spending UK£234k on shares in just twelve months. This, combined with the lack of sales from insiders, should be a great signal for shareholders in what's to come. We also note that it was the CEO & Director, Liam Condon, who made the biggest single acquisition, paying UK£134k for shares at about UK£13.42 each. Johnson Matthey's earnings per share have been soaring, with growth rates sky high. Growth-minded people will be intrigued by the incredible movement in EPS growth. And indeed, it could be a sign that the business is at an inflection point. If this these factors intrigue you, then an addition of Johnson Matthey to your watchlist won't go amiss. You still need to take note of risks, for example - Johnson Matthey has 4 warning signs (and 1 which is a bit concerning) we think you should know about. Keen growth investors love to see insider activity. Thankfully, Johnson Matthey isn't the only one. You can see a a curated list of British companies which have exhibited consistent growth accompanied by high insider ownership. Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
35 minutes ago
- Yahoo
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 9, Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and reduced the price target from $61 to $56. The reiteration comes after the company announced its commercial and distribution agreement with Avanzanite for its drug Pyrukynd in Europe, Switzerland, and the UK. The analyst said that the recent agreement of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) with Avanzanite mirrors its previously successful collaboration in the Gulf region. The agreement will enable the company to concentrate on the US market while leveraging Avanzanite's expertise in European rare disease markets. Moreover, Pyrukynd has already been approved for pyruvate kinase deficiency and is expected to receive FDA approval for thalassemia and potentially EMA approval in 2026. A technician in a lab looks off into the distance, showcasing the research taking place at Agios Pharmaceuticals. Analyst Emily Bodnar lowered the price target due to the agreement's revenue split which initially benefits Avanzanite. However, Bodnar views it as a capital-efficient way to accelerate Agios' entry and revenue growth in Europe. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company specializing in developing innovative therapies for patients with rare diseases. Its main product, Pyrukynd (mitapivat), is the first disease-modifying treatment for adults with pyruvate kinase deficiency, a form of hemolytic anemia. While we acknowledge the potential of AGIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
7% yields and low P/E ratios? These 2 cheap shares look promising!
While hunting for high-yield opportunities on the FTSE All-Share, I recently identified two cheap shares that look undervalued. For income-focused investors, finding companies offering both strong dividends and modest valuations can be a powerful combination. I tend to look for businesses with low price-to-earnings (P/E) ratios, high dividend yields and solid free cash flow. These are often signs the market has overlooked potential value. After some digging, two stocks caught my attention: MAN Group (LSE: EMG) and International Personal Finance (LSE: IPF). MAN Group's one of the world's largest publicly-listed hedge fund firms with a £1.97bn market-cap and a long track record in quantitative and alternative strategies. The shares currently trade for around £1.70 and have a P/E ratio of only 8.7, which is low compared to the financial sector average. One of the major advantages here is MAN's capital-light business model. With relatively low fixed costs and scalable operations, the company can maintain strong margins even during volatile market conditions. In fact, market volatility often benefits the firm, as it drives higher performance and management fees. On top of that, the 7.35% dividend yield looks attractive, especially given the company's history of special dividends and share buybacks. However, there are risks. The company's revenue is closely tied to asset performance and investor sentiment. If markets turn sour, performance fees can dry up quickly. There's also the macroeconomic angle – rising rates and geopolitical shocks could weigh on investor appetite for hedge fund strategies. Still, for those seeking a cheap stock with income potential, MAN Group seems worth considering, in my opinion. With a P/E ratio of just 6 and a £1.56 price tag, this up-and-coming finance stock looks like one of the cheapest shares on the FTSE All-Share. The £345m company offers consumer credit services in emerging markets, primarily in Eastern Europe and Latin America. While the sector carries more risk than blue-chip financials, the returns can be compelling. Plus, the company has a long track record of awarding cash to its dedicated shareholders, currently sporting a dividend yield of 7.15%. A key strength is the firm's local knowledge. The company operates with in-country teams who understand regional lending conditions and maintain close contact with customers. This face-to-face model helps keep default rates manageable, even in less stable economies. On the flip side, international operations expose it to currency fluctuations and political instability, which can threaten earnings. Regulatory changes are another challenge, particularly if governments impose interest rate caps or tighten lending criteria. Moreover, funding costs could rise if global interest rates stay elevated. Still, with both a high yield and room for growth, I think it's a stock worth further research. Both MAN Group and International Personal Finance offer an attractive combination of cheap shares with high dividends. They're not without risks, but the low valuations suggest much of the bad news may already be priced in. For investors comfortable with a bit of market volatility, these two stocks could provide meaningful passive income while trading at a discount. The post 7% yields and low P/E ratios? These 2 cheap shares look promising! appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
